Bionomics (ASX: BNO) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Bionomics Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Bionomics (ASX: BNO)
Latest News
Share Gainers
These 3 ASX Healthcare shares have soared over 10% today
Share Market News
Up almost 1000% in 1 year, the Bionomics (ASX:BNO) share price moves higher
Share Market News
Why the Bionomics (ASX:BNO) share price is climbing today
Share Market News
Why the Bionomics (ASX:BNO) share price surged 8% higher today
Speculative
Bionomics share price jumps 17% on subscription agreement
Share Gainers
Why the Bionomics share price rocketed 43% higher today
Share Market News
US congressman resigns over ASX insider trading penny stock scandal
Share Market News
Paradigm reports "ground-breaking" osteoarthritis discovery: Is it the real deal?
Share Market News
Why the Bionomics share price is up 40% today
Share Fallers
Warning: These are the 10 worst small-cap shares of FY 2019
Share Fallers
Why the Bionomics share price crashed 37.5% lower today
Share Gainers
Why Altura Mining, Appen, Bionomics, & Newcrest shares climbed higher today
BNO ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Bionomics
Bionomics Ltd. is a clinical stage biopharmaceutical company. It engages in the development of novel drug candidates focused on the treatment of serious central nervous system disorders. The company was founded in 1996 and is headquartered in Eastwood, Australia.
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Alan David Fisher | Non-Executive Director | Sep 2016 |
Mr Fisher is an experienced corporate advisor and public company director. He has a track record for implementing strategies that enhance shareholder value. His main areas of expertise include mergers and acquisitions, public and private equity raisings, business restructurings and strategic advice. He is Chair of the Risk Management Committee.
|
Mr Aaron Weaver | Non-Executive Director | Jul 2020 |
Mr Weaver is a Principal at Apeiron Investments Group Ltd (Apeiron), focused on the life sciences and technology sector. From 2013 - 2017, he was an investment banker at Credit Suisse Group AG in London within the Capital Markets Solutions team, advising on capital structuring and issuances for a full spectrum of corporate issuers from pre-revenue companies to public listed companies. He was a capital markets solicitor at Allen & Overy LLP, London from 2007 - 2013. Mr Weaver currently serves on the board of Bionomics as Apeiron's nominee. He is a director of MagForce AG, LEAF4Life LLC, Alto Neuroscience, Endogena Therapeutics, Inc, Rejuveron Life Sciences AG.
|
Dr Errol B De Souza | Executive ChairmanExecutive Director | Aug 2016 |
Dr De Souza is a leader in the development of therapeutics for treatment of central nervous system (CNS) disorders. He has experience as an executive in the biopharmaceutical industry, having founded companies (Neurocrine Biosciences Inc.) and served as President and CEO of several public (Biodel Inc.; Synaptic Pharmaceutical Corp.) and private (Archemix Corp. and Neuropore Therapies Inc.) biotech companies. Dr De Souza has raised several hundred million dollars in capital in private and public sectors and has taken companies public (Neurocrine Biosciences IPO) and sold companies (Synaptic sale to Lundbeck) to provide liquidity and build shareholder value. Over Dr De Souza's career, he has served in a number of high-ranking R&D roles, including SVP and US head of R&D for Aventis (1998-2002), co-founder and EVP of R&D at Neurocrine (1992-1998) and Head of CNS at DuPont Merck (1990-1992). Dr De Souza has served on multiple editorial boards, National Institutes of Health (NIH) Committees and is currently a Director of several public and private companies and currently serves as a member of the board of directors of Catalyst Biosciences, Inc. (CBIO), Cyclerion Therapeutics (CYCN) and Royalty Pharma plc (RPRX). He has previously served on the board of directors of several public companies including IDEXX Laboratories (IDXX), Neurocrine Biosciences (NBIX), Palatin Technologies (PTN) and Synaptic Pharmaceuticals (SNAP).
|
Mr David Ian Wilson | Non-Executive Director | Jun 2016 |
Mr Wilson is Chairman and founding partner of WG Partners LLP and has over 35 years' experience in investment banking in the City of London. Previously Mr Wilson was CEO of Piper Jaffray Ltd, where he also served as Global Chairman of Healthcare and on the Group Leadership Team. Mr Wilson has held senior positions at ING Barings as Joint Head of UK Investment Banking Group, Deutsche Bank as Head of Small Companies Corporate Finance and UBS as Head of Small Companies Corporate Broking. Mr Wilson was previously Senior Independent Director of Optos plc, a Non-Executive Director of BerGenBio AS. He is member of the Risk Management Committee.
|
Dr Jane Ryan | Non-Executive Director | Sep 2020 |
Dr Ryan has over 30 years of international experience in the pharmaceutical and biotechnology industries having worked in Australia, US and UK. She has held senior executive roles in management of research and development programs as well as business development and alliance management. Throughout her career, she has led many fundraising campaigns and licensing initiatives. She is member of the Risk Management Committee.
|
Mr Peter Miles Winston Davies | Non-Executive Director | Jul 2021 |
Mr Davies is a 15-year veteran of the financial services industry with multi-sector and multi-function experience. He has a track record in advising private and public company Board of Directors and shareholders of businesses. He has completed numerous M&A transactions across a variety of sectors including healthcare, along with experience in capital raising and restructuring opportunities during his time at Rothschild & Co. Mr Davies is currently an Investment Professional at Apeiron Investments Group Ltd and is Chief Business Officer for Leaf4Life Inc
|
Dr Spyridon Papapetropoulos | Non-Executive Director | Jan 2023 |
--
|
Ms Suzanne Grace Irwin | Company Secretary | Apr 2021 |
-
|
Adrian Hinton | Acting Chief Financial Officer |
-
|
|
Suzanne Grace Irwin | Company Secretary |
-
|
|
Liz Doolin | Vice President Clinical Development |
-
|
|
Connor Bernstein | Vice President Strategy and Corporate Development |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Citicorp Nominees Pty Limited <Citibank Ny Adr Dep A/C> | 339,875,460 | 25.11% |
HSBC Custody Nominees (Australia) Limited | 318,042,650 | 23.50% |
BNP Paribas Nominees Pty Ltd Acf Clearstream | 73,460,960 | 5.43% |
BNP Paribas Noms Pty Ltd <DRP> | 43,985,676 | 3.25% |
HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> | 34,633,340 | 2.56% |
US Register Control A/C\C | 32,409,786 | 2.39% |
Bell Potter Nominees Ltd <Bb Nominees A/C> | 28,472,814 | 2.10% |
Citicorp Nominees Pty Limited | 20,002,049 | 1.48% |
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> | 17,995,687 | 1.33% |
Merrill Lynch (Australia) Nominees Pty Limited | 17,901,124 | 1.32% |
Mr Jason Howard David Camm | 9,102,132 | 0.67% |
L&M Group Limited | 8,884,085 | 0.66% |
BNP Paribas Noms Pty Ltd <Global Markets Drp> | 8,527,043 | 0.63% |
Forward Vision Vii Lp Series 2 | 6,830,075 | 0.50% |
Mr Mark Richard Potter + Mrs Rebecca Amy Potter <Mark & Rebecca Potter A/C> | 5,500,000 | 0.41% |
Qualvest Pty Ltd <Lin Super Fund A/C> | 5,000,000 | 0.37% |
Charmed5 Pty Ltd | 5,000,000 | 0.37% |
Ambria Investors Lp | 4,845,050 | 0.36% |
Provendore Pty Ltd <The Wilks Super Fund A/C> | 4,418,550 | 0.33% |
Welas Pty Ltd <The Wales Family Super A/C> | 4,403,719 | 0.33% |